Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma

Sponsor
University of California, Davis (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT01316523
Collaborator
Celgene (Industry)
30
Enrollment
2
Locations
1
Arm
144
Anticipated Duration (Months)
15
Patients Per Site
0.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Lenalidomide has been shown to have single agent activity in indolent Non-Hodgkin's Lymphoma. It is approved for the treatment of multiple myeloma and myelodysplastic syndrome.

Rituximab is effective as a single agent and in combination with chemotherapy for indolent Non-Hodgkin's Lymphoma.

The purpose of this study is to see how well giving lenalidomide together with rituximab works in treating patients with previously untreated indolent Non Hodgkin's Lymphoma.

Lenalidomide will taken at 20 mg daily, days 1-21 of a 28 day cycle, to be continued until the disease progresses, unacceptable side effects or after twelve cycles if the patient is responding well.

Rituximab 375 mg/m2/wk x 4 weeks will begin on Day 15 of cycle 1. After 4 cycles of therapy, if patients respond well to treatment, patients will receive a second course of Rituximab.

Blood samples will be collected to assess how the immune system is functioning.

Condition or DiseaseIntervention/TreatmentPhase
Phase 2

Study Design

Study Type:
Interventional
Actual Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Phase II Study of Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non Hodgkin's Lymphoma
Actual Study Start Date :
Dec 1, 2010
Anticipated Primary Completion Date :
Jun 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

ArmIntervention/Treatment
Experimental: Lenalidomide + Rituximab

Patients will receive lenalidomide 20 mg daily (oral), on days 1-21 of a 28 day cycle. Rituximab 375 mg/m2 (into the vein) will be administered weekly for 4 doses starting day 15 of cycle 1, to be repeated if patient does not achieve a complete response after cycle 4, on days 1, 8, 15 and 22 of cycle 5.

Drug: Rituximab
Rituximab 375 mg/m2/wk x 4 weeks, to begin Day 15 of cycle 1. After 4 cycles of therapy if patient does not respond to treatment, the patient will receive a second course of Rituximab.
Other Names:
  • Rituxan
  • Drug: Lenalidomide
    Lenalidomide will be taken at 20 mg daily, days 1-21 of a 28 day cycle, to be continued until the disease progresses, there are too many side effects, or after twelve cycles if the patient responds to treatment.
    Other Names:
  • Revlimid
  • Outcome Measures

    Primary Outcome Measures

    1. Response rate to treatment [4 months]

      Responses will be assessed by the Revised Working Group Response Criteria for Malignant Lymphoma. A complete response is the complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. A partial response is regression of measurable disease and no new sites of disease. Stable disease is failure to attain a complete response/partial response or progressive disease.

    Secondary Outcome Measures

    1. Time to progression [Up to two years.]

      Time to progression will be measured as the time from when the patient started treatment to the time the patient is first recorded as having disease progression, or the date of death if the patient dies due to causes other than disease progression

    2. Overall survival [Up to two years.]

      Overall survival wil be measured as the time from start of treatment to the date of death or the last date the patient was known to be alive

    3. Tolerability defined by frequency, severity and relationship of adverse events to study treatment [Up to two years.]

      Tolerability means the type, frequency, severity and relationship of adverse events to study treatment based on the National Cancer Institute Common Toxicity Criteria Version 4.0

    4. Duration of response from start of therapy [Up to two years.]

      The duration of response is measured from the time measurement criteria are met for complete response/partial response(whichever status is recorded first) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started). The duration of response is measured from the time measurement criteria are first met for complete response until the first date that recurrent disease is objectively documented.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. All patients must be informed of the investigative nature of the clinical trial and given written informed consent in accordance with institutional and federal guidelines.

    2. Age greater than or equal to 18 years at the time of signing the informed consent form.

    3. Able to adhere to the study visit schedule and other protocol requirements.

    4. Previously untreated, histologically confirmed indolent lymphoma including follicle cell lymphoma, WHO classification, grade I or II, and marginal zone lymphoma. Bone marrow biopsies as the sole means of diagnosis are not acceptable, but they may be submitted in conjunction with nodal biopsies. Fine needle aspirates are not acceptable.

    5. At least one measurable lesion according to the International Working Group Response criteria for lymphomas. There must be measurable lymphadenopathy to follow with serial exam and/or imaging.

    6. Submission of original biopsy for review by local staff hematopathologist.

    7. ECOG performance status of 0 -2 at study entry.

    8. No major organ dysfunction with laboratory test results within these ranges:

    • Absolute neutrophil count greater than or equal to 1000 /uL

    • Platelet count greater than or equal to 75 x 109/L

    • Total bilirubin less than or equal to 2.0 mg/dL.

    • HIV negative

    • Subjects must have calculated creatinine clearance ≥ 30ml/min by Cockcroft-Gault formula. See section below, "Dosing Regimen", regarding lenalidomide dose adjustment for calculated creatinine clearance ≥ 30ml/min and < 60ml/min.

    1. Life expectancy of greater than 3 months.

    2. Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14 days prior to and again within 24 hours of starting lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure.

    3. Disease free of prior malignancies for greater than or equal to 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast

    4. Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation. (patients who are intolerant to aspirin may use low molecular weight heparin).

    5. Must be able to swallow lenalidomide capsules.

    Exclusion Criteria:
    1. Any prior treatment for Non-Hodgkin's Lymphoma.

    2. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.

    3. Pregnant or breast-feeding females. (Lactating females must agree not to breast feed while taking lenalidomide).

    4. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.

    5. Use of any other experimental drug or therapy within 28 days of baseline.

    6. Known hypersensitivity to thalidomide or rituximab.

    7. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.

    8. Any prior use of lenalidomide.

    9. Concurrent use of other anti-cancer agents or treatments.

    10. Known positive for HIV

    11. Known active hepatitis, type A, B or C.

    12. Evidence for CNS metastatic disease

    13. Subjects with ≥ Grade 2 neuropathy

    Contacts and Locations

    Locations

    SiteCityStateCountryPostal Code
    1University of California Davis Cancer CenterSacramentoCaliforniaUnited States95817
    2Sutter Pacific Medical FoundationSanta RosaCaliforniaUnited States95403

    Sponsors and Collaborators

    • University of California, Davis
    • Celgene

    Investigators

    • Principal Investigator: Joseph Tuscano, MD, University of California, Davis

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Joseph Tuscano, Professor, Department of Internal Medicine, University of California, Davis
    ClinicalTrials.gov Identifier:
    NCT01316523
    Other Study ID Numbers:
    • 215856
    • UCDCC#224
    • RV_PI_NHL_0488
    First Posted:
    Mar 16, 2011
    Last Update Posted:
    Nov 24, 2021
    Last Verified:
    Nov 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Joseph Tuscano, Professor, Department of Internal Medicine, University of California, Davis
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 24, 2021